NEOGENOMICS INC

NeoGenomics operates a network of cancer-focused laboratory testing facilities serving the United States and United Kingdom markets. The company provides diagnostic testing services to hospitals, academic medical centers, pathologists, oncologists, and clinical laboratories, as well as pharmaceutical companies conducting oncology research and development programs. Its service offerings span multiple testing methodologies including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry with digital imaging, and molecular analysis of DNA and RNA structures. The company also performs morphologic analysis—microscopic examination of cellular samples by pathologists—and supports pharmaceutical clients' oncology programs from discovery through commercialization phases.

The laboratory operates across two primary business segments: clinical oncology diagnostics and pharmaceutical services. Clinical diagnostics represent the core business, involving analysis of tissue and blood samples for cancer detection, classification, and treatment guidance. The pharmaceutical services segment supports drug development activities for oncology-focused clients seeking molecular and cytogenetic testing capabilities.

NeoGenomics maintains approximately 2,500 full-time employees across its laboratory locations and support operations. The company was incorporated in Nevada and is headquartered in Fort Myers, Florida, with its primary market presence in the United States supplemented by operations in the United Kingdom. The company was founded in 2001 and trades on the Nasdaq exchange under the ticker symbol NEO.